Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Intuitive Surgical

This article was originally published in The Gray Sheet

Executive Summary

Initial public offering of up to $50 mil. in common stock is outlined in a preliminary prospectus filed with the Securities and Exchange Commission. Founded in November 1995, the Mountain View, California company is developing a tele-robotic instrumentation system for minimally invasive surgery. The device's three components include a surgeon's control console with 3D visual display, patient-side cart that holds electromechanical instrument manipulators, and surgical instruments designed for use through small (1 cm) incisions. Although Intuitive, which plans initially to pursue cardiac surgery indications, has already gained 510(k) clearance for the console, patient-side cart and "certain blunt resposable instruments," regulatory clearance for certain other instruments is necessary prior to commercialization, the firm explains. A clinical trial is slated to begin in July under a March investigational device exemption in order to obtain data requested by FDA for use of the instruments in certain thoracoscopic and laparoscopic surgical procedures. Net proceeds from the IPO are tabbed for continued R&D, clinical trials, manufacturing scale-up, expansion of marketing and sales capabilities, and other corporate purposes. Morgan Stanley Dean Witter, Bear Stearns and BT Alex. Brown are underwriters for the offering

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts